Vicriviroc
- Generic Name
- Vicriviroc
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C28H38F3N5O2
- CAS Number
- 306296-47-9
- Unique Ingredient Identifier
- TL515DW4QS
- Background
Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was developed by Schering-Plough.
- Indication
Investigated for use/treatment in HIV infection and viral infection.
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
- Conditions
- Interventions
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 41
- Registration Number
- NCT03631407
- Locations
- 🇺🇸
California Cancer Associates for Research & Excellence ( Site 0100), Encinitas, California, United States
🇺🇸Baylor Scott & White Medical Center - Temple ( Site 0104), Temple, Texas, United States
🇨🇦Cross Cancer Institute ( Site 0201), Edmonton, Alberta, Canada
Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents
- First Posted Date
- 2008-10-06
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 9
- Registration Number
- NCT00766597
- Locations
- 🇺🇸
Chicago Children's CRS, Chicago, Illinois, United States
🇵🇷Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, Puerto Rico
🇺🇸Children's National Med. Ctr. Washington DC NICHD CRS, Washington, District of Columbia, United States
Effect of Vicriviroc on HIV Ribonucleic Acid (RNA) Levels in Cerebrospinal Fluid (Study P05241)
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 13
- Registration Number
- NCT00632073
Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)
- Conditions
- Interventions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 111
- Registration Number
- NCT00551330
Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)
- Conditions
- Interventions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 218
- Registration Number
- NCT00551018
Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)
- Conditions
- Interventions
- First Posted Date
- 2007-08-31
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 506
- Registration Number
- NCT00523211
Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)
- Conditions
- Interventions
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 400
- Registration Number
- NCT00474370
Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285
- Conditions
- First Posted Date
- 2005-10-24
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00243568
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.